Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (64)

2024

  1. Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

  2. Multidisciplinary management of type 2 inflammation diseases using a screening tool

    Frontiers in Allergy, Vol. 5

  3. Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

  4. Pursuing precision in medicine and nutrition: the rise of electrochemical biosensing at the molecular level

    Analytical and Bioanalytical Chemistry, Vol. 416, Núm. 9, pp. 2151-2172

  5. Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

    Clinical Cancer Research

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  3. Editorial: Multi-omics data integration: key to thoroughly understanding the immune system

    Frontiers in Cell and Developmental Biology

  4. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  5. TMeB score may improve risk stratification of high-risk cutaneous squamous cell carcinoma and guide management of patients: A pilot study

    Journal of the European Academy of Dermatology and Venereology

2022

  1. Evolutionary Origins of Metabolic Reprogramming in Cancer

    International journal of molecular sciences, Vol. 23, Núm. 20

  2. New functions of C3G in platelet biology: Contribution to ischemia-induced angiogenesis, tumor metastasis and TPO clearance

    Frontiers in Cell and Developmental Biology, Vol. 10

  3. Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer

    Cancers, Vol. 14, Núm. 2

  4. TRAF3 alterations are frequent in del-3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 903-914

2021

  1. Aradyal: The spanish multidisciplinary research network for allergic diseases

    Journal of Investigational Allergology and Clinical Immunology, Vol. 31, Núm. 2, pp. 108-119

  2. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  3. From biomarkers to models in the changing landscape of chronic lymphocytic leukemia: Evolve or become extinct

    Cancers, Vol. 13, Núm. 8

  4. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment

    Diagnostics, Vol. 11, Núm. 5

2020

  1. C3G contributes to platelet activation and aggregation by regulating major signaling pathways

    Signal Transduction and Targeted Therapy, Vol. 5, Núm. 1

  2. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612